• Sols

  Participated · Seed · Jan 2014

  SOLS makes custom 3D-printed shoe insoles created from a mobile-app foot scan and processing algorithms that factor in height, weight, lifestyle and intended use. The company has focused on doctor-prescribed orthotics and has grown from dozens of prescribing doctors to over 300 medical professionals offering its products. SOLS has planned consumer-facing distribution and aims to address athletes’ needs with its custom inserts. The product pricing for resold insoles was cited in the $300–$700 range. The company added Dallas Mavericks president and CEO Terdema Ussery to its board and counts Carmelo Anthony as an investor. With the new round, SOLS has raised a total of $19.3 million to date. SOLS Systems produces 3D-printed dynamic orthotics using a proprietary computer vision system that converts images or brief videos into precise 3D models of the foot. The model, combined with patient body, lifestyle and medical-need data, is used to generate fully custom, precision-engineered orthotics. The company is preparing custom mass-manufacturing platforms to support a direct-to-consumer launch planned for 2015. It intends to use its new funding to accelerate team growth (the team is now 12 people) and product development. SOLS Systems was founded and is led by CEO Kegan Schouwenburg. The company previously closed a $1.75m seed round in December 2013. SOLS produces custom 3D-printed antimicrobial nylon insoles that are polished and coated for a soft, rubbery feel and offered in multiple colors and leather. Customers scan their feet with an iOS or Android app; SOLS combines that 3D scan with weight, lifestyle and use-case data to generate a bespoke insole. The company is initially targeting the medical market with a beta program of fifteen doctors and plans a consumer launch afterward. Patient pricing for the medical program is expected to be around $300–$500, with a goal to reduce consumer pricing to about $100 upon broader launch. SOLS plans partnerships with shoe manufacturers and retailers for in-store scanning and fit-to-shoe options, and expects to expand city-by-city after launching in New York. The company has raised seed funding to support product development and rollout, and ALM is a strategic partner on materials and production.

• MC10

  Participated · Series B · Jun 2011

  MC10 develops stretchable sensor technology, marketed under its BioStamp name, for use in medical devices and other applications. The company has partnered with Medtronic to integrate BioStamp into a balloon catheter intended to open vessels while simultaneously collecting data on heart function and potential vascular problems. MC10 also struck a deal with Reebok to produce a head-worn device that gauges head-trauma severity in contact sports; the product is not designed as a diagnostic but to help reduce the risk of serious injury. Financially, MC10 reported a $19.8M equity financing in a regulatory filing, adding to an $18M funding round in April. The recent filing did not disclose the investors for the latest round; prior backers named in reporting include Braemar Energy Ventures, North Bridge Venture Partners, and Medtronic. MC10 develops conformable electronics that stretch, bend and twist, reshaping rigid conventional electronics into thin, flexible devices. The company's products are designed to be wearable and virtually invisible, conforming to the human body and the natural world. MC10's stated mission is to extend human capabilities by making high-performance electronics conformal and affordable for everyday consumers. The firm emphasizes transforming rigid electronics into devices that seamlessly stretch, bend and twist with bodies and the natural world. MC10 is based in Cambridge, MA. The company recently filed an SEC amendment adding $8 million to a previously filed $10 million round. Mc10 develops ultrathin, flexible electronic systems and sensors that can be placed inside or outside the body to monitor blood pressure, brain activity, muscle function and hydration. Rather than miniaturizing traditional electronics, the company focuses on turning them into flexible, 'invisible' systems that conform to human skin. Early commercial focus is consumer health and fitness; one of its first products, developed with Reebok, is a skullcap for athletes that records helmet impacts and alerts sideline personnel. The company aims to serve consumer, digital health and medical device markets and says strategic partnerships will accelerate time-to-market. Mc10 is a roughly 30-person Cambridge, Mass.-based startup with scientific advisors including Professor George Whitesides and Dr. Marvin Slepian. Financially, the company raised $10 million in this funding round and has received $33 million in total funding to date. MC10 designs thin, conformal and stretchable integrated electronics that move with the body and environment. The company is developing interventional circuits that can diagnose and influence tissue function and ‘seamless sensing’ devices to monitor ECG, EEG, EMG, body temperature, and hydration. MC10 combines breakthrough technology with engineering to create consumer, medical, and industrial products that blur the lines between user and device. The firm recently closed a $2 million follow-on investment from Aberdare Ventures, which also added its managing partner to MC10’s board. MC10 is headquartered in Cambridge, Massachusetts. Company leadership emphasizes the convergence of technology and healthcare as central to its strategy and product roadmap. MC10, based in Cambridge, MA, develops "electronic skin"—thin, sticker-like sensors that measure heart rate, activity level and hydration. The company targets health, wellness and healthcare markets as well as consumer and industrial applications. It intends to use newly raised funds to expand commercialization across medical device and healthcare applications. MC10 raised an additional $2.25M from Windham Venture Partners, bringing its Series B round to $14.75M. The company is actively hiring.

No current team members are available.